These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 10889166)

  • 21. Management of hepatitis B in China.
    Yao GB
    J Med Virol; 2000 Jul; 61(3):392-7. PubMed ID: 10861652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.
    Da Silva LC; Pinho JR; Sitnik R; Da Fonseca LE; Carrilho FJ
    J Gastroenterol; 2001 Jul; 36(7):476-85. PubMed ID: 11480792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
    Chien RN; Liaw YF; Atkins M
    Hepatology; 1999 Sep; 30(3):770-4. PubMed ID: 10462384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon.
    Hartman C; Berkowitz D; Shouval D; Eshach-Adiv O; Hino B; Rimon N; Satinger I; Kra-Oz T; Daudi N; Shamir R
    Pediatr Infect Dis J; 2003 Mar; 22(3):224-9. PubMed ID: 12634582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF; Tsai SL; Chien RN; Yeh CT; Chu CM
    Hepatology; 2000 Sep; 32(3):604-9. PubMed ID: 10960456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term lamivudine therapy for chronic hepatitis B in patients with and without cirrhosis.
    Oh JM; Kyun J; Cho SW
    Pharmacotherapy; 2002 Oct; 22(10):1226-34. PubMed ID: 12389873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants for sustained HBeAg response to lamivudine therapy.
    Chien RN; Yeh CT; Tsai SL; Chu CM; Liaw YF
    Hepatology; 2003 Nov; 38(5):1267-73. PubMed ID: 14578866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A study on the treatment of chronic hepatitis B with YMDD mutation].
    Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.
    Chang ML; Chien RN; Yeh CT; Liaw YF
    J Hepatol; 2005 Jul; 43(1):72-7. PubMed ID: 15896869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy and safety in chronic hepatitis B adolescent patients with lamivudine therapy].
    Lu WL; Xie DY; Yao JL; Yao GB; Cui ZY; Zhang DF; Wu L
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):429-31. PubMed ID: 15268810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.
    Schiff ER; Dienstag JL; Karayalcin S; Grimm IS; Perrillo RP; Husa P; de Man RA; Goodman Z; Condreay LD; Crowther LM; Woessner MA; McPhillips PJ; Brown NA;
    J Hepatol; 2003 Jun; 38(6):818-26. PubMed ID: 12763376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.
    Liaw YF; Chien RN; Yeh CT; Tsai SL; Chu CM
    Hepatology; 1999 Aug; 30(2):567-72. PubMed ID: 10421670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.